Use of MRI for Personalized Treatment of More Aggressive Tumors

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

“…Baricitinib and Ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis [114] , which are currently reused for the treatment of SARS-CoV-2 infected patients. Studies have confirmed the safety and effectiveness of these drugs in reducing cytokine levels in the treatment of COVID-19 as antiviral drugs [115] , [116] , [117] . In addition, Baricitinib has the effect of reducing the endocytosis of the SARS-CoV-2 [118] .…”